Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection aims to wake muscles after surgery

NCT ID NCT07195604

Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a single dose of HRS-2162 injection in 64 healthy volunteers to see if it is safe and how the body processes it. The drug is designed to reverse neuromuscular blockade, a temporary muscle paralysis used during surgery. Researchers will monitor side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HRS-2162 injection
What this could lead to
If successful, this could lead to a new option for quickly reversing muscle paralysis after surgery or in emergency settings.
What could go wrong
This is an early Phase 1 trial in only 64 healthy people, so safety and effectiveness are not yet proven. It may not work as hoped or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The subjects voluntarily signed the informed consent form. 2. Applicants must be between 18 and 45 years old at the time of signing the informed consent form, and both men and women are eligible . 3. ASA classification is Grade I (only Parts Two and three) 4. Male weight ≥50 kg, female weight ≥45 kg, body mass index between 19 and 28 kg/m ². 5. Adopt efficient contraceptive measures Exclusion Criteria: 1. Those with a past or current clinical acute or chronic disease 2. Those with a history of hereditary bleeding or coagulation disorders or non-traumatic bleeding . 3. Those with a history of neuromuscular diseases or poliomyelitis 4. Those with a history of anesthesia complications. 5. Those whose laboratory test results during the screening period or baseline period exceed the normal range and have clinical significance 6. The blood pressure of the subjects was abnormal and was judged by the researchers to be of clinical significance 7. The subject has a history of severe systemic allergies for any reason. 8. The subjects took steroid hormone drugs within 7 half-lives or 14 days before administrationSmoke ≥5 cigarettes per day within 3 months prior to the study. 9. History of drug abuse. 10. Those who the researchers considered unsuitable for inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Reversal of neuromuscular blockade are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Reversal of neuromuscular blockade

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sichuan Academy of Medical Sciences &Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, 610072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.